Stock analysts at StockNews.com assumed coverage on shares of OpGen (NASDAQ:OPGN – Get Free Report) in a research note issued on Sunday. The brokerage set a “sell” rating on the medical research company’s stock.
OpGen Trading Up 3.5 %
Shares of OPGN stock opened at $1.95 on Friday. OpGen has a 12 month low of $1.40 and a 12 month high of $9.90. The stock has a 50 day moving average of $1.84 and a 200-day moving average of $2.54.
OpGen (NASDAQ:OPGN – Get Free Report) last issued its quarterly earnings results on Monday, August 19th. The medical research company reported ($1.18) earnings per share for the quarter. The business had revenue of $0.03 million for the quarter.
OpGen Company Profile
OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.
See Also
- Five stocks we like better than OpGen
- What is a Death Cross in Stocks?
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
- What is the S&P/TSX Index?
- Freeport-McMoRan, Copper Demand Short-Term Pain, Long-Term Gain
- Most Volatile Stocks, What Investors Need to Know
- Time to Load Up on Home Builders?
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.
